GlassScriptPhysician profile
Brandon M Smith
NPI 1558611822
$228.41
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $17.19.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $55.53 | 2021 | |
| Abbvie INC. | $49.80 | 2021-2022 | |
| Amgen INC. | $28.47 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.42 | 2021 | |
| Genentech USA, INC. | $18.36 | 2021 | |
| Abbott Laboratories | $16.75 | 2021 | |
| Lilly USA, LLC | $15.03 | 2021 | |
| Novo Nordisk INC | $14.92 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.